Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine

Trial Profile

Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms Zotrip
  • Sponsors Zosano Pharma
  • Most Recent Events

    • 26 Jun 2017 According to a company media release, Zosano received confirmation that this single efficacy study is sufficient to support an NDA filing for M207.
    • 12 Jun 2017 Additional results from this trial published in a Zosano Pharma Media Release.
    • 12 Jun 2017 According to a Zosano Pharma media release, additional data from this trial were presented at the 59th Annual Scientific Meeting of the American Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top